SILO PHARMA SECURES NOTICE OF ALLOWANCE IN JAPAN FOR SPC-15, ENHANCING GLOBAL INTELLECTUAL PROPERTY ASSETS
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 18 2026
0mins
Should l Buy SILO?
Source: moomoo
- Company Announcement: Silo Pharma has received a notice of allowance in Japan for its SP-15 product.
- Global Expansion: This development is part of Silo Pharma's strategy to expand its global intellectual property portfolio.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy SILO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on SILO
About SILO
Silo Pharma, Inc. is a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company. The Company’s therapeutic focus is on addressing underserved conditions, including stress-induced psychiatric disorders, chronic pain, and central nervous system (CNS) diseases. The Company’s portfolio includes programs, such as for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimer’s disease and multiple sclerosis. Its lead product candidate, SPC-15, is designed as a novel serotonin 4 (5-HT4) receptor agonist that utilizes biomarkers for treatment of stress-induced psychiatric disorders such as PTSD and anxiety disorders. SPC-14 targets glutamate receptor NDMAR and serotonin 5-HT4 to address cognitive and neuropsychiatric symptoms in Alzheimer’s disease. SPU-16 is a candidate targeting central nervous system (CNS) disorders, with an initial indication for multiple sclerosis.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Silo Pharma Authorizes $1 Million Share Repurchase Program
- Share Repurchase Program: Silo Pharma's board has authorized a share repurchase program of up to $1 million, which is expected to enhance investor confidence and potentially boost stock prices, thereby improving the company's market performance in the biopharmaceutical sector.
- Stock Price Surge: Following the announcement, SILO shares rose 32.75% to $0.37 in premarket trading, indicating positive market sentiment regarding the company's future, particularly in its drug development efforts.
- R&D Progress: The company plans to submit an IND application for SPC-15 to the FDA this year as a treatment for PTSD and stress-induced anxiety disorders, which, if approved, will initiate the first-in-human trial and further advance the commercialization of its product pipeline.
- Financial Performance: For the quarter ended September 30, 2025, Silo Pharma reported a wider net loss of $1.20 million, or $0.19 per share, while license revenue remained flat, highlighting the need for cost control measures to achieve sustainable growth.
See More
Keysight Technologies Quarterly Earnings Beat Estimates
- Strong Earnings Performance: Keysight Technologies reported earnings per share of $2.17, exceeding Wall Street's expectation of $2, demonstrating robust profitability that boosts investor confidence.
- Significant Revenue Growth: The quarterly revenue reached $1.6 billion, surpassing the analyst consensus of $1.54 billion, indicating successful business expansion and strong market demand, further solidifying its market position.
- Stock Price Surge: Keysight's shares jumped 16.8% to $286.03 in pre-market trading, reflecting a positive investor reaction to the company's financial performance, which may attract more investor interest.
- Market Dynamics Impact: Keysight's strong results could influence the performance of other related stocks, particularly in the technology and electronics sectors, signaling an overall improvement in market sentiment.
See More
Silo Pharma Approves $1M Share Buyback Program
- Buyback Program Initiated: Silo Pharma has approved a share repurchase program to buy back up to $1 million of its common stock, aiming to enhance earnings per share and boost investor confidence by reducing the number of shares outstanding.
- Strong Stock Performance: As of November 13, 2025, the company had 13.32 million shares of common stock outstanding, and the implementation of the buyback program is expected to further elevate the stock price, attracting more investor interest.
- Positive Market Reaction: Following the announcement of the buyback program, SILO shares surged 45.8% in after-hours trading, indicating a bullish market sentiment towards the company's future prospects, which may draw in more institutional investors.
- Clear Strategic Positioning: As a developmental-stage biotech firm, Silo Pharma focuses on integrating traditional therapeutics with psychedelic research, and the buyback program will provide financial support for its future R&D and market expansion efforts.
See More
SILO PHARMA SECURES NOTICE OF ALLOWANCE IN JAPAN FOR SPC-15, ENHANCING GLOBAL INTELLECTUAL PROPERTY ASSETS
- Company Announcement: Silo Pharma has received a notice of allowance in Japan for its SP-15 product.
- Global Expansion: This development is part of Silo Pharma's strategy to expand its global intellectual property portfolio.
See More
Silo Pharma Partners with Allucent to Advance SPC-15 Clinical Studies
- Clinical Research Collaboration: Silo Pharma has signed a Letter of Intent with global CRO Allucent to conduct two Phase 1 studies for its SPC-15 nasal spray, marking a significant advancement in the treatment of psychiatric disorders.
- Study Design Details: The studies will include an Open-Label Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) design, aimed at efficiently generating safety and pharmacokinetic data to expedite SPC-15's clinical development.
- Strategic Importance: CEO Eric Weisblum stated that this collaboration will enhance the rigor and speed of the research, further advancing SPC-15's development to provide new therapies for PTSD and anxiety patients.
- Product Background: SPC-15 is an investigational intranasal 5-HT4 receptor agonist designed for rapid brain action using a special soft mist delivery system, with plans to leverage biomarkers for an accelerated FDA approval pathway.
See More
Silo Pharma Enters LOI with Allucent for SPC-15 Clinical Studies
- Clinical Research Collaboration: Silo Pharma has signed a Letter of Intent with global CRO Allucent to conduct two Phase 1 studies for its SPC-15 nasal spray, marking a significant advancement in the treatment of PTSD and anxiety.
- Agreement Details: The LOI outlines comprehensive support for clinical operations, pharmacovigilance, and data management, which is expected to accelerate the clinical development of SPC-15, enhancing the company's competitiveness in the biopharmaceutical sector.
- Drug Development Context: SPC-15 is an investigational intranasal 5-HT4 receptor agonist targeting stress-induced psychiatric conditions, aiming for rapid brain action to alleviate PTSD and anxiety symptoms, indicating its potential market value.
- Long-term Value Creation: The CEO of Silo Pharma stated that this collaboration will facilitate the efficient generation of safety and pharmacokinetic data, further driving innovation and long-term growth in the mental health space.
See More
Silo Pharma Authorizes $1 Million Share Repurchase Program
- Share Repurchase Program: Silo Pharma's board has authorized a share repurchase program of up to $1 million, which is expected to enhance investor confidence and potentially boost stock prices, thereby improving the company's market performance in the biopharmaceutical sector.
- Stock Price Surge: Following the announcement, SILO shares rose 32.75% to $0.37 in premarket trading, indicating positive market sentiment regarding the company's future, particularly in its drug development efforts.
- R&D Progress: The company plans to submit an IND application for SPC-15 to the FDA this year as a treatment for PTSD and stress-induced anxiety disorders, which, if approved, will initiate the first-in-human trial and further advance the commercialization of its product pipeline.
- Financial Performance: For the quarter ended September 30, 2025, Silo Pharma reported a wider net loss of $1.20 million, or $0.19 per share, while license revenue remained flat, highlighting the need for cost control measures to achieve sustainable growth.
See More
Keysight Technologies Quarterly Earnings Beat Estimates
- Strong Earnings Performance: Keysight Technologies reported earnings per share of $2.17, exceeding Wall Street's expectation of $2, demonstrating robust profitability that boosts investor confidence.
- Significant Revenue Growth: The quarterly revenue reached $1.6 billion, surpassing the analyst consensus of $1.54 billion, indicating successful business expansion and strong market demand, further solidifying its market position.
- Stock Price Surge: Keysight's shares jumped 16.8% to $286.03 in pre-market trading, reflecting a positive investor reaction to the company's financial performance, which may attract more investor interest.
- Market Dynamics Impact: Keysight's strong results could influence the performance of other related stocks, particularly in the technology and electronics sectors, signaling an overall improvement in market sentiment.
See More
Silo Pharma Approves $1M Share Buyback Program
- Buyback Program Initiated: Silo Pharma has approved a share repurchase program to buy back up to $1 million of its common stock, aiming to enhance earnings per share and boost investor confidence by reducing the number of shares outstanding.
- Strong Stock Performance: As of November 13, 2025, the company had 13.32 million shares of common stock outstanding, and the implementation of the buyback program is expected to further elevate the stock price, attracting more investor interest.
- Positive Market Reaction: Following the announcement of the buyback program, SILO shares surged 45.8% in after-hours trading, indicating a bullish market sentiment towards the company's future prospects, which may draw in more institutional investors.
- Clear Strategic Positioning: As a developmental-stage biotech firm, Silo Pharma focuses on integrating traditional therapeutics with psychedelic research, and the buyback program will provide financial support for its future R&D and market expansion efforts.
See More
SILO PHARMA SECURES NOTICE OF ALLOWANCE IN JAPAN FOR SPC-15, ENHANCING GLOBAL INTELLECTUAL PROPERTY ASSETS
- Company Announcement: Silo Pharma has received a notice of allowance in Japan for its SP-15 product.
- Global Expansion: This development is part of Silo Pharma's strategy to expand its global intellectual property portfolio.
See More
Silo Pharma Partners with Allucent to Advance SPC-15 Clinical Studies
- Clinical Research Collaboration: Silo Pharma has signed a Letter of Intent with global CRO Allucent to conduct two Phase 1 studies for its SPC-15 nasal spray, marking a significant advancement in the treatment of psychiatric disorders.
- Study Design Details: The studies will include an Open-Label Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) design, aimed at efficiently generating safety and pharmacokinetic data to expedite SPC-15's clinical development.
- Strategic Importance: CEO Eric Weisblum stated that this collaboration will enhance the rigor and speed of the research, further advancing SPC-15's development to provide new therapies for PTSD and anxiety patients.
- Product Background: SPC-15 is an investigational intranasal 5-HT4 receptor agonist designed for rapid brain action using a special soft mist delivery system, with plans to leverage biomarkers for an accelerated FDA approval pathway.
See More
Silo Pharma Enters LOI with Allucent for SPC-15 Clinical Studies
- Clinical Research Collaboration: Silo Pharma has signed a Letter of Intent with global CRO Allucent to conduct two Phase 1 studies for its SPC-15 nasal spray, marking a significant advancement in the treatment of PTSD and anxiety.
- Agreement Details: The LOI outlines comprehensive support for clinical operations, pharmacovigilance, and data management, which is expected to accelerate the clinical development of SPC-15, enhancing the company's competitiveness in the biopharmaceutical sector.
- Drug Development Context: SPC-15 is an investigational intranasal 5-HT4 receptor agonist targeting stress-induced psychiatric conditions, aiming for rapid brain action to alleviate PTSD and anxiety symptoms, indicating its potential market value.
- Long-term Value Creation: The CEO of Silo Pharma stated that this collaboration will facilitate the efficient generation of safety and pharmacokinetic data, further driving innovation and long-term growth in the mental health space.
See More
